Xiaoyang Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoyang Zhao has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bingqing Xu
Department of Oncology, Yichang Central People's Hospital & The First College of Clinical Medical Science of Three Gorges University, Yichang, China
1 shared publication - Dong Liu
State Key Laboratory of Food Nutrition and Safety Tianjin University of Science & Technology Tianjin China
1 shared publication - Duncan Spalding
Department of HPB Surgery, Imperial College Healthcare NHS Trust, London W2 1NY, UK
1 shared publication - Fashui Hong
Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr & E, Huaian 223300, Peoples R China
1 shared publication - Hao Jiang
Department of Psychology and Behavioural Sciences, Zhejiang University, Hangzhou, Zhejiang Province, China
1 shared publication Hongchi Jiang
Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
1 shared publication
Latest Publications
- 14 January 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (18) , 3446-3457
Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is generally accompanied by high mortality and low cure rate. CCAAT enhancer-binding proteins (CEBPs) are transcriptional regulators that play a key role in maintaining liver function. Altered expression of C/EBPα and C/EBPβ occurs in many tumours including HCC. saRNAs are small double-stranded RNAs that enhance target gene expression at the transcriptional level. In this report, we activate CEPBA with saRNAs and suppress CEBPB with siRNAs in cells that represent three different degrees of HCC. We performed functional assays to investigate the effects of enhancing C/EBPα and its downstream targets, p21 and albumin across these lines. We also used Mass-spectrometry (MS) subsequent to a ChIP pull-down assay to characterise the components of the protein complex involved in regulating saRNA function. Putative saRNA interacting protein candidates that were identified by MS were knocked-down with siRNAs to investigate its impact on saRNA activity. We confirmed CEBPA-saRNA decreased proliferation and migration in the differentiated lines (HepG3/Hep3B). The undifferentiated line (PLCPRF5) showed saRNA-induced increase in CEBPA but with no loss in proliferation. This effect was reversed when CEBPB was suppressed with CEBPB-siRNA. When interrogating saRNA mode of action; three saRNA interacting proteins, CTR9, HnRNPA2/B1 and DDX5 were identified by MS. Targeted knock-down of these two proteins (by siRNA) abrogated saRNA activity. This study provides insight into how different HCC lines are affected by CEBPA-saRNAs and that endogenous abundance of CEBPB and saRNA accessory proteins may dictate efficacy of CEBPA-saRNA when used in a therapeutic context.
- 14 January 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (18) , 3446-3457
Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is generally accompanied by high mortality and low cure rate. CCAAT enhancer-binding proteins (CEBPs) are transcriptional regulators that play a key role in maintaining liver function. Altered expression of C/EBPα and C/EBPβ occurs in many tumours including HCC. saRNAs are small double-stranded RNAs that enhance target gene expression at the transcriptional level. In this report, we activate CEPBA with saRNAs and suppress CEBPB with siRNAs in cells that represent three different degrees of HCC. We performed functional assays to investigate the effects of enhancing C/EBPα and its downstream targets, p21 and albumin across these lines. We also used Mass-spectrometry (MS) subsequent to a ChIP pull-down assay to characterise the components of the protein complex involved in regulating saRNA function. Putative saRNA interacting protein candidates that were identified by MS were knocked-down with siRNAs to investigate its impact on saRNA activity. We confirmed CEBPA-saRNA decreased proliferation and migration in the differentiated lines (HepG3/Hep3B). The undifferentiated line (PLCPRF5) showed saRNA-induced increase in CEBPA but with no loss in proliferation. This effect was reversed when CEBPB was suppressed with CEBPB-siRNA. When interrogating saRNA mode of action; three saRNA interacting proteins, CTR9, HnRNPA2/B1 and DDX5 were identified by MS. Targeted knock-down of these two proteins (by siRNA) abrogated saRNA activity. This study provides insight into how different HCC lines are affected by CEBPA-saRNAs and that endogenous abundance of CEBPB and saRNA accessory proteins may dictate efficacy of CEBPA-saRNA when used in a therapeutic context.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1179-S1180
Assessing the Impact and Benefits of Radiofrequency-Assisted Parenchymal Sparing Liver Resection on Post-Hepatectomy Liver Failure
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1179-S1180
Assessing the Impact and Benefits of Radiofrequency-Assisted Parenchymal Sparing Liver Resection on Post-Hepatectomy Liver Failure
- 20 November 2014
- Published by Wiley in Environmental Toxicology
- Vol. 31 (6) , 655-662
TiO2nanoparticle-induced neurotoxicity may be involved in dysfunction of glutamate metabolism and its receptor expression in mice
Titanium dioxide nanoparticles (TiO2 NPs) have been used in environmental management, food, medicine, and industry. But TiO2 NPs have been demonstrated to cross the blood–brain barrier and store up in the brain organization, leading to glutamate‐mediated neurotoxicity. However, the neurotoxicity in the brain is not well understood. In this study, mice were exposed to 1.25, 2.5, or 5 mg/kg body weight TiO2 NPs for 9 months, and the glutamate–glutamine cyclic pathway and expressions of glutamate receptors associated with the hippocampal neurotoxicity were investigated. Our findings showed elevations of glutamate release and phosphate‐activated glutaminase activity, and reductions in glutamine and glutamine synthetase in the hippocampus following exposure to TiO2 NPs. Furthermore, TiO2 NPs significantly inhibited the expression of N‐methyl‐d‐aspartate receptor subunits (including NR1, NR2A, and NR2B) and metabotropic glutamate receptor 2 in mouse hippocampus. These findings suggest that the imbalance of glutamate metabolism triggered inhibitions of glutamate receptor expression in the TiO2 NP‐exposed hippocampus. © 2014 Wiley Periodicals, Inc. Environ Toxicol 31: 655–662, 2016.
- 20 November 2014
- Published by Wiley in Environmental Toxicology
- Vol. 31 (6) , 655-662
TiO2nanoparticle-induced neurotoxicity may be involved in dysfunction of glutamate metabolism and its receptor expression in mice
Titanium dioxide nanoparticles (TiO2 NPs) have been used in environmental management, food, medicine, and industry. But TiO2 NPs have been demonstrated to cross the blood–brain barrier and store up in the brain organization, leading to glutamate‐mediated neurotoxicity. However, the neurotoxicity in the brain is not well understood. In this study, mice were exposed to 1.25, 2.5, or 5 mg/kg body weight TiO2 NPs for 9 months, and the glutamate–glutamine cyclic pathway and expressions of glutamate receptors associated with the hippocampal neurotoxicity were investigated. Our findings showed elevations of glutamate release and phosphate‐activated glutaminase activity, and reductions in glutamine and glutamine synthetase in the hippocampus following exposure to TiO2 NPs. Furthermore, TiO2 NPs significantly inhibited the expression of N‐methyl‐d‐aspartate receptor subunits (including NR1, NR2A, and NR2B) and metabotropic glutamate receptor 2 in mouse hippocampus. These findings suggest that the imbalance of glutamate metabolism triggered inhibitions of glutamate receptor expression in the TiO2 NP‐exposed hippocampus. © 2014 Wiley Periodicals, Inc. Environ Toxicol 31: 655–662, 2016.